A Walk in the PARP: Therapeutic Strategies Targeting DNA Repair Defects in Prostate Cancer

A Walk in the PARP: Therapeutic Strategies Targeting DNA Repair Defects in Prostate Cancer

Thursday, February 14, 2019
Webinar -- 7:00 PM PT


7:00 PM - 7:10 PM Welcome and Introduction

7:10 PM - 7:30 PM Practical Guidance on the Clinical Role of BRCA and Other DNA Damage Repair Genes in Prostate Cancer – David A. Quigley, PhD

7:30 PM - 7:50 PM Intersection of Germline and Tumor Genetic Testing in Prostate Cancer – Celestia S. Higano, MD, FACP

7:50 PM - 8:10 PM Targeting DNA Repair Defects in Prostate Cancer: The Role of PARP Inhibitors – Charles J. Ryan, MD

8:10 PM - 8:30 PM Applying the Data to Practice: Panel Case Discussion and Audience Question and Answer Session


Program Director
Celestia S. Higano, MD, FACP

Departments of Medicine and Urology
University of Washington
Seattle, Washington

David Quigley, PhD/ND/EdD

Assistant Adjunct Professor
Department of Epidemiology and Biostatistics
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Charles Ryan, MD

Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
 Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into the treatment of patients with prostate cancer.

Target Audience
This program is intended for oncologists and urologists and other healthcare providers who care for patients with prostate cancer.

Learning Objectives 

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or other DNA damage response mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.